Key Points
• The authors of this narrative review explored the most important predictive biomarkers in advanced non-small cell lung cancer (NSCLC). Here are their results with respect to EGFR.
• In advanced lung adenocarcinoma, EGFR is the main actionable target with a mutation frequency of 15% in Whites and 40% Asians.
• Nearly all...
Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review
Source : https://pcm.amegroups.com/article/view/6062
Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review
Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33842645/
Immunotherapy has been proved to be a promising candidate for advanced non-small cell lung cancer (NSCLC). Despite MET mutations are regarded as an independent factor of programmed death ligand 1...
-
NSCLC Connect5yrKey Points • Case study indicating that NSCLC with METex14 had a significant response to anti-PD-1 therapy. Even though targeted therapy has become the mainstay regimen of NSCLC with METex14, treatment-resistant genes Show More
CircRNA_100395 Carried by Exosomes From Adipose-Derived Mesenchymal Stem Cells Inhibits the Malignant Transformation of Non-Small Cell Lung Carcinoma Through the miR-141-3p-LATS2 Axis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33842488/
doi: 10.3389/fcell.2021.663147. 1 Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. 2 Department of Medical Oncology, Shulan (Hangzhou) Hospital, Affiliated to Shulan International...
The Fusion Gene Landscape in Taiwanese Patients with Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33809651/
1 Epigenome Research Center, China Medical University Hospital, Taichung 404332, Taiwan. 2 Department of Laboratory Medicine, China Medical University Hospital, Taichung 404332, Taiwan. 3 Center for Precision Medicine, China Medical...
Neoadjuvant Nivolumab plus Chemotherapy Increased Pathological Complete Response Rate in CheckMate-816 Lung Cancer Trial | AACR | News Releases
PHILADELPHIA - Adding nivolumab (Opdivo) to chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC) produced significant improvement of pathological complete response (pCR, primary endpoint) rate...